PR Newswire·Sep 22, 2026, 10:39 AM ET

First patient treated with Leqembi® (lecanemab) in Sweden

BioArctic AB announced that Leqembi is now available at a private clinic in Sweden, marking the first patient treatment outside of a clinical study since EU approval in April 2025.
The first patient, treated at Executive Health in Stockholm, received the therapy after the New Therapies Council gave a negative recommendation for public healthcare funding in April 2026.
Leqembi is indicated for adults with mild cognitive impairment or mild dementia due to Alzheimer's disease who are ApoE ε4 non-carriers or heterozygotes with confirmed amyloid pathology.
CEO Gunilla Osswald stated the treatment addresses an unmet need to slow disease progression & reduce the burden on patients, care partners, & society, noting the therapy is based on 20+ years of research by Professor Lars Lannfelt.
Leqembi was developed through a long-standing collaboration between BioArctic & Eisai, with BioArctic holding commercialization rights in the Nordic region.
BioArctic has no development costs for Leqembi in Alzheimer's disease & is entitled to sales milestone payments & royalties on global sales.
Leqembi is approved in 53 countries & subcutaneous dosing was recently approved in China & Japan in September 2026.
Eisai continues ongoing Phase 3 clinical studies (AHEAD 3-45 & Tau NexGen) for preclinical & dominantly inherited Alzheimer's disease respectively.
BioArctic is a Swedish biopharma company focused on neurodegenerative diseases, with its B shares listed on Nasdaq Stockholm.